TARP as antigen in cancer immunotherapy.

Jolien Vanhooren, Charlotte Derpoorter, Barbara Depreter, Larissa Deneweth, Jan Philippé, Barbara De Moerloose, Tim Lammens

Cancer immunology, immunotherapy : CII 2021 Nov

filter terms:

In recent decades, immunotherapy has become a pivotal element in cancer treatment. A remaining challenge is the identification of cancer-associated antigens suitable as targets for immunotherapeutics with potent on-target and few off-tumor effects. The T-cell receptor gamma (TCRγ) chain alternate reading frame protein (TARP) was first discovered in the human prostate and androgen-sensitive prostate cancer. Thereafter, TARP was also identified in breast and endometrial cancers, salivary gland tumors, and pediatric and adult acute myeloid leukemia. Interestingly, TARP promotes tumor cell proliferation and migration, which is reflected in an association with worse survival. TARP expression in malignant cells, its role in oncogenesis, and its limited expression in normal tissues raised interest in its potential utility as a therapeutic target, and led to development of immunotherapeutic targeting strategies. In this review, we provide an overview of TARP expression, its role in different cancer types, and currently investigated TARP-directed immunotherapeutic options. © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Citation

Jolien Vanhooren, Charlotte Derpoorter, Barbara Depreter, Larissa Deneweth, Jan Philippé, Barbara De Moerloose, Tim Lammens. TARP as antigen in cancer immunotherapy. Cancer immunology, immunotherapy : CII. 2021 Nov;70(11):3061-3068